Processivity and drug-dependence of HIV-1 protease: Determinants of viral fitness in variants resistant to protease inhibitors

AIDS

Volumn 17, Issue 5, 2003, Pages 663-671

  Menzo, Stefano ^a   Monachetti, Alessia ^a   Balotta, Claudia ^b   Corvasce, Stefano ^b   Rusconi, Stefano ^b   Paolucci, Stefania ^c   Baldanti, Fausto ^c   Bagnarelli, Patrizia ^a   Clementi, Massimo ^d,e  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Drug dependence; Enzyme processivity; HIV 1 fitness; Protease inhibitors

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

CLONING, MOLECULAR; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; POINT MUTATION; VIRUS REPLICATION;

EID: 0037471312     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303280-00003     Document Type: Article

References (35)

1. Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001, 26 (suppl. 1):34-50.
2. Shafer D, Dupnik K, Winters M, Eshleman S. A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Sequence Compendium 2000, Los Alamos HIV Sequence Database. Los Alamos, New Mexico, USA: Los Alamos National Laboratory, 2000.
3. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high level rsistance to protease inhibitors. J Virol 1997, 71:1089-1096.
4. Borman A, Paulous S, Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996, 77:419-426.
5. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998, 72:7632-7637.
6. Nijhuis M, Boucher C, Schipper P, Leitner T, Schuurman R, Albert J. Stochastic process strongly influence HIV-1 evolution during sub-optimal protease-inhibitor therapy. Proc Natl Acad Sci USA 1998, 95:14441-14446.
7. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996, 70:3763-3769.
8. Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol 2000, 49:41-66.
9. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998, 72:3300-3306.
10. de la Carriere L, Paulous S, Clavel F, Mammano F. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J Virol 1999, 73:3455-3459.
11. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and the presence of drug. J Virol 2000; 74:8524-8532.
12. Martinez-Picado J, Savara A, Shi L, Sutton L, D'Aquila R. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000, 275:318-322.
13. Prado J, Wrin T, Beauchaine J, Ruiz L, Petropoulos C, Frost S, et al. Amprenavir resistant HIV-1 exhibits Iopinavir cross-resistance and reduced replication capacity. AIDS 2002, 16:1009-1017.
14. Holland J, de la Torre J, Clarke D, Duarte E. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J Virol 1991, 65:2960-2967.
15. Domingo E, Holland J. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997, 51:151-178.
16. Goudsmit J, De Ronde A, Ho D, Perelson A. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996, 70:5662-5664.
17. Goudsmit J, De Ronde A, de Rooij E, de Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codon 41 and 215. J Virol 1997, 71:4479-4484.
18. Devereux H, Emery V, Johnson M, Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001, 65:218-224.
19. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilemburg AB, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse trancritase enzyme. EMBO J 1996, 15:4040-4049.
20. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Schipper P, et al. Increased fitness of drug resistant protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999, 13:2349-2359.
21. Maeda Y, Venzon D, Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998, 177:1207-1213.
22. Sharma P, Crumpacker C. Attenuated replication of human immunodeficiency virus type 1 with didanosine-selected reverse transcriptase mutation. J Virol 1997, 71:8846-8851.
23. Bleiber G, Munoz M, Ciuffi A, Meyelan P, Talenti A. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication and protein maturation of antiretroviral drug-rsistant human immunodeficiency virus type 1. J Virol 2001, 75:3291-3300.
24. Menzo S, Rusconi S, Monachetti A, Colombo M, Violin M, Bagnarelli P, et al. Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single step strategy. AIDS 2000, 14:1-10.
25. Rusconi S, LaSeta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, et al. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000, 44:1328-1332.
26. Larder B, Hertogs K, Bloor S, van den Eynde C, DeCian W, Freimuth W, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV clinical samples. AIDS 2000, 14:1943-1948.
27. Dupont S, Sharova N, DéHoratius C, Virbasius C-MA, Zhu X, Bukrinskaya A, et al. A novel nuclear export activity in HIV-1 matrix protein required for viral replication. Nature 1999, 402:681-685.
28. Bukrinskaya A, Brichacek B, Mann A, Stevenson M. Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med 1998, 188:2113-2125.
29. Tisdale M, Myers R, Maschera B, Parry N, Oliver N, Blair E. Cross-resistance analysis of human immunodeficiency virus 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995, 39:1704-1710.
30. Condra J, Schleif W, Blahy O, Gabryelski L, Graham D, Quintero J, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
31. Condra J, Holder D, Schleif W, Blahy O, Danovich R, Gabryelski L, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
32. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper P, Mo H, et al. Ordered accumulation of mutations in HIV protease confer resistance to ritonavir. Nat Med 1996, 2:760-766.
33. Patick A, Duran M, Cao Y, Shugarts D, Keller M, Mazabel E, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998, 42:2637-2644.
34. Perno C, Cozzi-Lepri A, Balotta C, Bertoli A, Violin M, Monno L, et al. Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS 2002, 16:619-624.
35. Perno C, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001, 184:983-991.